Billionaire Kumar Mangalam Birla on Thursday promised a massive investment and unveiled a new identity of the company. The ...

Alvotech acquires Xbrane’s R&D operations and the biosimilar candidate XB003. Xbrane retains some pre-clinical development programs, that it intends to commercialize, and will continue operating as a ...

“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...

The "Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies, RNAi-Based Therapeutics), Application (Diabetes, Cancer), Dosage Form, ...

Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension This partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and pain ...

Korean Air has launched a new corporate branding - including updating its logo for the first time since 1984 - as it works ...

IN celebration of its 43rd anniversary, the Manila International Airport Authority (MIAA) on Friday night revealed its new logo. The airport authority's new logo consists of a Philippine eagle with ...

According to Cipla, the regulatory clearance serves as an important landmark in the Company's journey, allowing it to expand the depth of its oncology portfolio and its foothold in the US market ...

February 28, 2025 Tariffs should not dictate how Indian drugmakers do business, Cipla CEO says Tariffs should ... An index of Indian pharmaceutical company shares slid 2% to its lowest level ...

Amy is an ACA and the CEO and founder of OnPoint Learning, a financial training company delivering training to financial professionals. She has nearly two decades of experience in the financial ...

However, where competition is limited, the impact would more likely be passed on. Nomura highlighted that the Cipla management comments were “largely aligned with our views . We highlighted that ...

Cipla has recently fallen below its 20-day Exponential Moving Average, currently standing at a price of Rs 1460.3. Today, it has experienced a change of -1.11%, with the 20-day EMA noted at 1460.34.